论文部分内容阅读
[目的]观察神经节苷脂对进展性脑卒中患者的临床疗效及对血浆S100β的影响。[方法]2010年1月至2011年1月,86例急性进展性脑卒中患者随机分为两组,对照组43例仅采用常规治疗,观察组43例在常规治疗基础上应用神经节苷脂治疗,比较观察两组的临床效果和血浆S100β的变化。[结果]观察组的基本治愈率和总有效率均明显高于对照组(P﹤0.05)。两组治疗后神经功能缺损评分明显降低,与治疗前水平比较差异有统计学意义(P﹤0.05)。观察组治疗后神经功能缺损评分明显低于同期对照组水平(P﹤0.05)。两组治疗后S100β水平明显降低,与治疗前水平比较差异有统计学意义(P﹤0.05)。观察组治疗后S100β水平明显低于同期对照组水平(P﹤0.05)。[结论]神经节苷脂对进展性脑卒中患者进行治疗能够明显提高临床疗效,改善患者神经功能状态,并且明显降低血浆S100β蛋白水平,值得临床推广应用。
[Objective] To observe the clinical effect of ganglioside on patients with progressive stroke and its effect on plasma S100β. [Methods] From January 2010 to January 2011, 86 patients with acute progressive stroke were randomly divided into two groups, 43 patients in the control group were treated with conventional therapy only, and 43 patients in the observation group were treated with gangliosides The clinical effects and the changes of plasma S100β were compared between the two groups. [Results] The basic cure rate and total effective rate in the observation group were significantly higher than those in the control group (P <0.05). The score of neurological deficit in the two groups after treatment was significantly lower than that before treatment (P <0.05). The score of neurological deficit in the observation group after treatment was significantly lower than that of the control group (P <0.05). The levels of S100β in the two groups after treatment were significantly lower than those before treatment (P <0.05). The level of S100β in the observation group was significantly lower than that in the control group (P <0.05). [Conclusion] Gangliosides treatment of patients with progressive stroke can significantly improve the clinical efficacy, improve neurological status, and significantly reduce the plasma level of S100β protein, worthy of clinical application.